# A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT01424930** · PHASE2 · COMPLETED · sponsor: **Janssen-Ortho Inc., Canada** · enrollment: 25 (actual)

## Conditions studied

- Prostate Neoplasms
- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01424930
- **Lead sponsor:** Janssen-Ortho Inc., Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-04
- **Final completion:** 2013-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424930, "A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01424930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*